Study reveals breast cancer can return years after the "all clear" – Experts already pushing to keep women on prescriptions longer (no mention of lifestyle)

(Natural News) The findings of a new study out of England have blown yet another hole in the conventional cancer therapy myth, revealing that women who undergo typical procedures like chemotherapy and radiation for breast cancer often see the deadly disease return – in some cases up to 20 years after they were supposedly “cured.”...
Source: - Category: Consumer Health News Source Type: news

Related Links:

Conclusion: The comprehensive advantage of high drug loading, redox-controlled drug release and targeted tumor accumulation suggests uPA-PTXD NPs as a highly promising strategy for effective TNBC treatment.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
CONCLUSION: NAC use for BC at these South African hospitals was associated with both tumor characteristics and heterogenous resource constraints. IMPLICATIONS FOR PRACTICE: Using data from a large breast cancer cohort treated in South Africa's public healthcare system, the authors looked at determinants of neoadjuvant chemotherapy use and time to initiate treatment. It was found that neoadjuvant chemotherapy was associated with increasing tumor burden and aggressive molecular subtypes, demonstrating clinically appropriate care in a lower resource setting. Results of this study also showed that time to treatment differ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Conclusions Therapy with IMed infusions in women with BC or gynecological cancer requires the same standards set for drug therapy. Although vitamins represent dietary supplements, appropriate assessment of the patient's medical history is needed and patients must receive appropriate information. For this purpose, standardized processes, as in the context of an IMed consultancy service, are helpful. PMID: 30498280 [PubMed]
Source: Geburtshilfe und Frauenheilkunde - Category: OBGYN Tags: Geburtshilfe Frauenheilkd Source Type: research
This article, however, is more of a commentary on high level strategy and the effects of regulation, coupled with a desire to forge ahead rather than hold back in the matter of treating aging, thus I concur with much more of what is said than is usually the case. For decades, one of the most debated questions in gerontology was whether aging is a disease or the norm. At present, excellent reasoning suggests aging should be defined as a disease - indeed, aging has been referred to as "normal disease." Aging is the sum of all age-related diseases and this sum is the best biomarker of aging. Aging and its d...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSION: The usage of subthreshold concentrations of muscarinic agonists combined with conventional chemotherapeutic agents could be a promising tool for breast cancer therapy. PMID: 30501602 [PubMed - as supplied by publisher]
Source: Current Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Clin Pharmacol Source Type: research
People who have undergone chemotherapy or radiotherapy suffer a reduced life expectancy and increased risk of suffering other age-related conditions even when the cancer is defeated. These cancer therapies produce large numbers of senescent cells, both as a result of their toxicity and because they force cancerous cells into senescence. It is quite likely that this is the primary mechanism by which successful cancer treatments nonetheless shorten later lifespan. This could be considered a true form of accelerated aging, as the accumulation of senescent cells is one of the root causes of aging. These cells secrete signals t...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
UCLA researchers have found that commonly used hormone therapies for women diagnosed with breast cancer do not appear to cause significant cognitive dysfunction following the treatment.Endocrine therapy has become an essential part of treatment for the many women diagnosed with hormone-receptor positive breast cancer, in which hormones, such as estrogen, promote cancer growth. The endocrine treatment helps lower the recurrence and reduce the risk of death from breast cancer by interfering with how a woman ’s own hormones can continue to support the growth of dormant cancer cells. Yet, there has been limited evidence ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
This study demonstrated the potential application of the novel 3D survivin promoter-EGFP reporter assay for high-throughput screening of chemicals down-regulating survivin as a molecular target for cancer therapy.
Source: Journal of Biotechnology - Category: Biotechnology Source Type: research
In this study, we interrogated the US Surveillance Epidemiology and End Results (SEER) registry to analyze the risks of ALL in cancer patients treated with RT, CT or combined modality regimens at the population level.MethodsWe used our previously validated R program, SEERaBomb (Leukemia 2016; 30: 285-94) to query all 18 SEER registries, 1973-2014. We identified all first cancer cases treated with RT and/or CT that subsequently developed ALL ≥1 year after diagnosis of the first cancer. First cancer cases of lymphoid lineage were excluded. Diagnosis was derived from the International Classification of Diseases. Relative r...
Source: Blood - Category: Hematology Authors: Tags: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Improving Outcomes with Cellular Therapy Source Type: research
Conclusions: We have detected a significantly increased, more than 3 times the expected value, prevalence of CHIP among cancer survivors who had received myelotoxic chemotherapy. However, the distribution of mutations was typical for CHIP, without previously suggested over-representation of TP53. Further research is ongoing to determine whether presence of CHIP is related to a direct mutagenic effect of chemotherapy or competitive advantage of pre-existing CHIP clones after the hematopoietic stress of chemotherapy. Our data indicate that an affordable next-generation sequencing screen may be useful for detection of CHIP in...
Source: Blood - Category: Hematology Authors: Tags: 503. Clonal Hematopoiesis: Aging and Inflammation: Poster III Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Men | Study | Women